Patterson, Laurence - University of Bradford

个人简介

PhD (London) BSc Hons (Hertfordshire)

研究领域

Tumour-selective drug activation The glycocalyx as a target for drug discovery Modulators of integrin activity Inhibitors of chemokines Bioreductive activation of drugs in hypoxia tumours Cytochromes P450 in tumours

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res. 2013 Apr 15. [Epub ahead of print] PubMed PMID: 23589180 Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1. PubMed PMID: 23033491 Falconer RA, Errington RJ, Shnyder SD, Smith PJ, Patterson LH. Polysialyltransferase: a new target in metastatic cancer. Curr Cancer Drug Targets. 2012 Oct;12(8):925-39. Review. PubMed PMID: 22463390 McMahon KM, Volpato M, Chi HY, Musiwaro P, Poterlowicz K, Peng Y, Scally AJ, Patterson LH, Phillips RM, Sutton CW. Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. J Proteome Res. 2012 May 4;11(5):2863-75. doi: 10.1021/pr2012472. Epub 2012 Mar 30. PubMed PMID: 22416669 Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14. PubMed PMID: 22002321 Veiga J.P., Cooper P.A., Pors K, Patterson L.H., Bibby M.C., Shnyder S.D. Use of the hollow fiber assay for the evaluation of DNA damaging agents. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. Epub 2011 Apr 30. PubMed PMID: 21569858 Vinader V, Al-Saraireh Y, Wiggins H.L., Rappoport J.Z., Shnyder S.D., Patterson L.H., Afarinkia K. An agarose spot chemotaxis assay for chemokine receptor antagonists. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):213-6. Epub 2011 Feb 1. PubMed PMID: 21292017 Atkinson J.M., Falconer R.A., Edwards D.R., Pennington C.J., Siller C.S., Shnyder S.D., Bibby M.C., Patterson L.H., Loadman P.M., Gill J.H. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res. 2010 Sep 1;70(17):6902-12. Epub 2010 Jul 27 PubMed PMID: 20663911; PubMed Central PMCID: PMC2933508 Sutton C.W., Sutherland M, Shnyder S, Patterson L.H. Improved preparation and detection of cytochrome P450 isoforms using MS methods. Proteomics. 2010 Jan;10(2):327-31. PubMed PMID: 19902426 Seibert C, Davidson B.R., Fuller B.J., Patterson L.H., Griffiths W.J., Wang Y. Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry. J Proteome Res. 2009 Apr;8(4):1672-81. PubMed PMID: 19714871; PubMed Central PMCID: PMC2939981 Sheldrake H.M., Patterson L.H. Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets. 2009 Jun;9(4):519-40. Review. PubMed PMID: 19519320 Abdallah Q.M., Phillips R.M., Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse R.T., Kiakos K, Bingham J.P., Hartley J.A., Patterson L.H., Pors K. Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. Biochem Pharmacol. 2012 Jun 1;83(11):1514-22. Epub 2012 Mar 1. PubMed PMID: 22387433